Early Introduction and Prolonged Full‐Dose Anakinra Reduce Recurrence Risk After Discontinuation in Recurrent Pericarditis: An International Multicenter Cohort

In patients with corticosteroid‐dependent, colchicine‐resistant recurrent pericarditis, durable drug‐free remission after anakinra discontinuation remains difficult to achieve, highlighting the need to identify predictors of successful treatment discontinuation. Early anakinra initiation and maintenance of full‐dose therapy for at least 6 months were independently associated with a lower risk of recurrence after treatment discontinuation. These findings support considering timely IL‐1 (interleukin 1) pathway inhibition and adequate full‐dose treatment duration when planning anakinra tapering and discontinuation, while requiring prospective validation.